Lutetium Oxodotreotide Lu-177: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lutetium Oxodotreotide Lu-177. Educational only — not medical advice.
Labeled uses
LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.
Source: FDA labeling via NIH DailyMed (set 72d1a024…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.